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Abstract
Background: Aurora kinases play critical roles in mitosis and are being evaluated as therapeutic targets in cancer.
GSK1070916 is a potent, selective, ATP competitive inhibitor of Aurora kinase B and C. Translation of predictive
biomarkers to the clinic can benefit patients by identifying the tumors that are more likely to respond to therapies,
especially novel inhibitors such as GSK1070916.
Methods: 59 Hematological cancer-derived cell lines were used as models for response where in vitro sensitivity to
GSK1070916 was based on both time and degree of cell death. The response data was analyzed along with
karyotype, transcriptomics and somatic mutation profiles to determine predictors of response.
Results: 20 cell lines were sensitive and 39 were resistant to treatment with GSK1070916. High chromosome
number was more prevalent in resistant cell lines (p-value = 0.0098, Fisher Exact Test). Greater resistance was also
found in cell lines harboring polyploid subpopulations (p-value = 0.00014, Unpaired t-test). A review of NOTCH1
mutations in T-ALL cell lines showed an association between NOTCH1 mutation status and chromosome number
(p-value = 0.0066, Fisher Exact Test).
Conclusions: High chromosome number associated with resistance to the inhibition of Aurora B and C suggests
cells with a mechanism to bypass the high ploidy checkpoint are resistant to GSK1070916. High chromosome
number, a hallmark trait of many late stage hematological malignancies, varies in prevalence among hematological
malignancy subtypes. The high frequency and relative ease of measurement make high chromosome number a
viable negative predictive marker for GSK1070916.
Background
Aurora kinases are an evolutionarily conserved protein
family required for a variety of mitotic functions including
chromosomal segregation, cell division events, and cyto-
kinesis. Aurora Kinase B (AURKB) is a serine/threonine
kinase and a component of the chromosome passenger
complex (CPC) responsible for regulation of cytokinesis
during mitosis. Aurora B localizes to the centromeres dur-
ing prometaphase and to the spindle midphase region dur-
ing anaphase onset to form a complex with survivin and
the inner centromere protein (INCENP) for regulation
and activation [1]. Aurora C is closely related to Aurora B
with overlapping functions and similar localization
patterns [2].
Aurora kinases are overexpressed in both solid and
hematological malignancies [3-8] and Aurora A
(AURKA) has been reported amplified in numerous
malignancies [9-11]. Since Aurora kinases are exclusively
expressed in proliferating cells, Aurora B inhibitors are
anticipated to have reduced side effects such as neuro-
toxicity commonly associated with chemotherapies
affecting tubulin in non-dividing cells (e.g. taxanes, vinca
alkaloids). These features make Aurora kinases attractive
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kinase inhibitors are currently being studied in early
phase I and II trials [12].
GSK1070916 is a selective inhibitor of AURKB/C and
has demonstrated anti-proliferative characteristics in
vitro and in vivo for both solid tumors as well as hema-
tological malignancies [13-15]. For many hematological
malignancies, few treatment alternatives have been
developed in recent years, and for many tumor subtypes
such as Acute Myeloid Leukemia (AML) and Non-
Hodgkin’s Lymphoma (NHL), significant challenges
remain. As with solid tumors, identification of predictive
biomarkers can accelerate the clinical development of
therapies for hematological malignancies through the
identification of the tumors most likely to respond. One
successful story of predictive biomarkers for hematologi-
cal malignancies is Imatinib (Gleevec) and the BCR-ABL
translocation commonly found in Chronic Mylogenous
Leukemia (CML).
Here, we report the evaluation of 67 hematological
tumor cell lines to identify predictive biomarkers for
GSK1070916. The cell line response data was compared
to the mutation patterns in the cell lines, gene expres-
sion patterns and the karyotypes of the cell lines. High
chromosome number in the cell lines was associated
with resistance to GSK1070916. Furthermore, treatment
with GSK1070916 generally elicited a polyploidy pheno-
type in the hematological cell lines; as has been seen
with Aurora B inhibitors. Conveniently, it is standard
clinical practice to perform karyotyping on hematologi-
cal cancer cells and chromosome number can serve as a
resistance marker for patient response to GSK1070916.
Methods
Cell Line Panel
Cell lines were purchased from the American Type Cul-
ture Collection [ATCC] and the German Resource Cen-
tre for Biological Material [DSMZ] and grown to
standard culture media recommended by the vendor.
The majority of the cell lines were used within 6 months
of acquisition and no re-authentication was performed.
For the DSMZ cell bank STR DNA typing is performed
for authentication and numerous authentication tests are
p e r f o r m e da tt h eA T C Cc e l lb a n k( S T R ,S e q u e n c i n g ,
SNP fingerprinting). Four cell lines in the panel (PLB-
985, SKO-007, J.RT3-T3.5, CEM/C1) were excluded from
analyses (data still provided in Additional File 1) since
they are subclones derived from parental cell lines
already on the panel (HL-60, U266, Jurkat, CCRF-CEM).
There are also four cell lines (GA10, 1A2, TO 175.t,
HUNS1) that are commercially available but not been
published as new cell lines so their characterization may
be incomplete. Cell cycle rates (doubling times) are also
provided for each cell line [Additional File 1, Table S1].
Cellular Proliferation Assays
Cells were seeded in 96-well white flat bottom plates
(NUNC #136102) in the recommended growth media
and incubated at 37°C in 5% CO2 overnight. The follow-
ing day, 2-fold serial dilutions of GSK1070916 starting at
10 or 20 μM for a 20 point titration curve were added to
the cell plates. The final DMSO concentration in all wells
was 0.2%. At the time of compound addition, one set of
cell plates was treated with CellTiter-Glo (Promega
#G7573) to determine the number of cells present at the
start of the treatment (T = 0). Following 6-7 day incuba-
tion with GSK1070916, CellTiter-Glo reagent was added
using a volume equivalent to the cell culture volume in
the wells. Plates were shaken and incubated at room tem-
perature for approximately 30 minutes and the chemilu-
minescent signal determined using the Envison 2100
(Perkin Elmer). For analysis of cell growth inhibition, the
d a t aw a sp l o t t e da st h ep e r c e n to ft h eD M S O - t r e a t e d
control samples and the data was fit using the IDBS
XLfit4 software for data analysis. Values from wells with
no cells were subtracted from all samples for background
correction.
Cell Cycle Analysis
Cells were seeded in 96-well plates in the recommended
growth media and incubated at 37°C in 5% CO2 over-
night. The following day, three fold serial dilutions from
556 nM to 7 nM of GSK1070916 were added and the
plates incubated for 24, 48 and 72 hours. After com-
pound treatment, the cells were processed for cell cycle
analysis using the detergent-trypsin Vindelov method
(Vindeløv, 1983). Briefly, the treated cells were washed
with PBS and suspended in 25 μl of citrate buffer
(40 mM Trisodium Citrate, 250 mM Sucrose, 5% DMSO,
pH 7.6) for 2 minutes. Next 100 μlo fS o l u t i o nA
(0.03 mg/ml Trypsin, 3.4 mM Trisodium Citrate, 0.5 mM
Tris Base, 0.1% NP40, 0.522 mg/ml spermine) was added
followed by the addition of 100 ul of solution B (0.5 mg/
ml Trypsin inhibitor (Sigma T-9003), 0.1 mg/ml of Rnase
A, 3.4 mM Trisodium Citrate, 0.5 mM Tris Base, 0.1%
NP40, 0.522 mg/ml spermine) for 10 minutes. The sam-
ples were then stained with the addition of 100 μlo f
Solution C (0.208 mg/ml propidium iodide, 1.682 mg/ml
spermine, 3.4 mM Trisodium Citrate, 0.5 mM Tris Base,
0.1% NP40) for 10 minutes in the dark. These steps were
all performed at room temperature while slowly shaking.
The stained samples were analyzed for their DNA con-
tent using a BD Biosciences FACScan Cytometer. For
each sample 3000 events were acquired on the BD
Bioscience FAScan flow cytometer and no gating was
applied. The instrument settings were applied so that the
2N-DNA peak on FL2-area histogram for each DMSO
treated cell line was aligned at 200 fluorescent units.
FL2-Area histograms were used to determine DNA
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which incorporates the Watson pragmatic algorithm.
Histograms were plotted as number of cellular events
versus FL-2-Area. DNA content was divided into 5
regions, sub-2N DNA, 2N DNA, 2N to 4N DNA, 4N
DNA and >4N DNA and the percentage of cellular
events in each of the five regions quantified.
Defining Cell Sensitivity
An analysis of cell line sensitivity to GSK1070916 was per-
formed with the data generated from screening cell lines
in cellular proliferation assays and from cell cycle analyses.
Cell lines were classified into one of three categories based
on the time when the majority of cells contained sub-2N
DNA (cell death) as determined by cell cycle analysis.
“Early” responders were defined as cell lines in which the
majority of cells contained sub-2N DNA within 48 hours
after compound treatment, “intermediate” required a 72
hour exposure, and “late” responders required greater
than or equal to a 96 hour exposure with GSK1070916 for
the majority of cells to contain sub2N DNA. Furthermore,
the Ymin (minimum response of the dose response curve)
and the T = 0 values (the number of cells at Time zero)
were determined from the cellular proliferation assays
with GSK1070916. Ymin values represent the bottom of
t h er e s p o n s ec u r v ea n dd e f i n et h el a r g e s te f f e c to ft h e
compound. These Ymin values are evaluated relative to
the number of cells at time zero using a Ymin/T0 ratio.
Response curves with values significantly below 1.0 are
considered cytotoxic while those above 1.0 are considered
cytostatic. Using the cell cycle response data and the
Ymin/T0 ratios, “Sensitive” cell lines were defined as cell
lines which were classified as an “early” or “moderate”
responders to GSK1070916 treatment by cell cycle analysis
(FACs) with a Ymin/T0 ratio of ≤ 0.5. Cell lines were clas-
sified as “Resistant” if they were “late” responders as
d e f i n e db yt h ec e l lc y c l ea n a l y s i sa n dh a dY m i n / T=0
ratios of > 0.5. Cell lines that were discordant between the
two measures were considered ambiguous and excluded
from the analysis. EC50 values greater than 500 were con-
sidered “resistant” regardless of cell cycle or Ymin values.
[Additional File 1, Table S1]
Karyotype and Mutation Data
Karyotype data included both G-banding and Spectral
Karytoyping (SKY) was collected from a variety of public
sources including the DSMZ [16], ATCC [17], and the
NCBI Sky collection [18]. These data contain important
karyotype information such chromosomal rearrange-
ments, chromosomal additions and deletions, transloca-
tions, modality (chromosome number) and other
notable structural changes in the genome. Karyotypes
were compiled with response profiles from GSK1070916
and reviewed for potential biomarker candidates.
[Additional File 1, Table S2]. Somatic mutation profiles
for genes implicated in tumorigenesis were collected
from the Catalogue of Somatic Mutations in Cancer
(COSMIC)[19] and are presented in Additional File 1,
Table S4.
Estimates of Patient Prevalence
To estimate the expected frequency of high chromo-
some number in the patient population, we reviewed
the Mitelman Database of Chromosome Aberrations in
Cancer [20].
Transcriptomics
mRNA transcript expression was quantified by using the
Affymetrix U133 Plus2 GeneChips in triplicate. First, cell
lines were plated in triplicate and lysed in TRIzol. Lysates
were captured with chloroform and purified using QIA-
GEN RNeasy Mini Kit (QIAgen, Inc., Valencia, CA).
cDNA was prepared from 5 μgt o t a lR N Au s i n gt h eI n v i -
trogen SuperScript Double-Stranded cDNA Synthesis Kit
(Invitrogen, Inc, Carlsbad, CA) and amplified using the
ENZO BioArray High-Yield RNA Transcript Labeling Kit
(Enzo Biochem, Inc. New York, NY). Finally, the samples
were fragmented and hybridized to the HG-U133Plus2
GeneChips, stained and scanned according to the manu-
facturer’s protocols. Transcript abundance was estimated
by normalizing all probe signal intensities were normal-
ized to a value of 150 using the mas5 algorithm in the
Affymetrix Microarray Analysis Suite 5.0. For subsequent
analysis, the average probe intensity was used for tripli-
cates. Values of mRNA abundance for Aurora A, B and C
are presented in Additional File 1, Table S4.
Kinase Screening
Enzymatic kinase screening assays for GSK7160916 were
performed by the Upstate Group http://www.upstate.
com using the KinaseProfiler to determine activity
across a range of kinases including the ABL kinase
oncogene.
Results
In Vitro Response Data
Based on proliferation, most of the hematological cell
lines were responsive to GSK1070916 with a median
EC50 of 7 nM. Since cancer cell death is a more desired
phenotype, the in vitro response of 91 hematological cell
lines were defined based on both time of response and
degree of cell death. 20/91 (22%) cell lines were desig-
nated sensitive and 39/91 (43%) cell lines were desig-
nated resistant (where sensitive and resistant is defined
in the Methods). Discordant values between prolifera-
tion and cell death were identified for 32 cell lines and
subsequently excluded, leaving 59 cell lines in the panel
for further analysis. The response of CML (4/6, 67%),
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lymphocytic leukemia (4/6, 67%) subtypes were among
the more sensitive subtypes. Conversely, T-cell Acute
lymphoblastic leukemia (1/6, 17%) B-cell lymphomas
(1/8, 13%) and Myelomas (0/3, 0%) were more resistant
among the different subtypes. (Figure 1; Additional
File 1, Table S1).
Modal Chromosome Number
In the analysis of the impact of chromosome number on
response, we found that most cell lines that were
approximately triploid or greater in chromosome number
(3n, > 69) were less sensitive to GSK1070916 (Figure 2).
This relationship with high chromosome number and
resistant phenotype was apparent in most hematological
subtypes, with exception of two cell lines, an AML line
(HL-60) and a CML line (EM-2). Notably, three CML
lines with hyperdiploidy (>2n) and hypertriploidy (>3n)
still showed sensitive response (HL-60, EM-2, KU-812).
In addition to inhibiting Aurora B and C, GSK1070916
also has activity for ABL (Additional File 1, Table S6)
which potentially contributes to the sensitivity observed
in these cell lines.
Comparison of the two response phenotypes for
modal chromosome number, using a chromosome
count of (3n) as the cutoff, showed a difference in the
response between the two cell line populations (p-value
= 0.0098, two-tailed Fisher Exact Test; Table 1). Using
the in-vitro data as a model for evaluating diploid chro-
mosome number as potential marker for patient selec-
tion provided reasonably high sensitivity in predicting
response rates (16/18 = 89%) but a lower specificity in
predicting those patients that would not respond to
treatment (13/27 = 48%). Not surprisingly, the negative
predictive value for low chromosome number was
higher (NPV = 14/16 = 88%) compared to the positive
predictive value (PPV = 16/33 = 49%).
Polyploidy in Tumor Subpopulations
In addition to the data for the primary chromosome
number, as used in Figure 2, karyotype data can be
reviewed for percentage of polyploidy in cell subpopula-
tions. For instance, the karyotype data for the TANOUE
cell line has a chromosome modal number of 48 for the
primary population of cells, but also 12% of the cell
population was polyploid (See Additional File 1, Table
S2 for karyotype data). To evaluate the effect these sub-
populations may have on response, we reviewed the
ploidy of cell subpopulations for cell lines with low/
diploid chromosome number (<50) in the primary popu-
lation (Figure 3). Interestingly, with the limited subset of
karyotype data available, we found that the average per-
centage of polyploid subpopulations was substantially
higher for the resistant cell lines compared to sensitive
cell lines in the panel. (7.9% vs. 1.2%, n = 28, p-value =
0.00014, Unpaired t-test, 95%, CI 0.0284- 0.1044) (Addi-
tional File 1, Table S3).
GSK1070916 Treatment Generates Polyploid Phenotype
Treatment of cancer cells with GSK1070916 yielded
phenotypes with polyploid DNA content resulting from
chromosome replication without nuclear or cell division.
A sensitive and diploid T-ALL cell line MOLT16, and a
polyploid and resistant T-ALL cell line CTV-1 were
treated with increasing concentrations of GSK1070916
for different time periods, and a flow cytometry study
was performed. For the sensitive cell line MOLT16, a
population of polyploid cells emerged within 24 hrs and
maintained their growth with increasing drug concentra-
tion. However, over longer period of drug treatment (48
hr and 72 hr), the percentage of polyploid cells were sig-
nificantly reduced, and there was a simultaneous
increase of sub-G1 population representing dead cells,
suggesting that the polyploid cells developed earlier
were not being tolerated and subsequently died. This is
in contrast to CTV-1, which exhibited much higher
levels of polyploidy cells and low cell death throughout
the study. (Figure 4)
Genetics Analysis
The background genetics of the hematological cell line
panel was reviewed in relation to Aurora inhibition by
GSK1070916. Expression profiles of Aurora A, B, and C
were evaluated in terms of response to Aurora inhibi-
tion and no association was observed (p-value = 0.79
and 0.96 respectively, unpaired t-test, Additional File 1,
Table S4).
In our response dataset, we observed 6 of the 7 T-
ALL cell lines with high chromosome number also had
Figure 1 Response profile of GSK1070916 for hematological
cell lines using cell cycle analysis and cell death measures to
determine sensitivity and resistance. Cell lines that are early and
moderate responders by cell cycle analysis with a Ymin/T0 ratio ≤
0.5 were considered sensitive (see METHODS).
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collected additional mutation data from public databases
for T-ALL cell lines (Additional File 1, Table S4). For
this dataset, a notable association with NOTCH1 and
high modal chromosome number was identified (Table
2, n = 23, p-value 0.0066, two-tailed Fisher Exact Test).
Prevalence of High Chromosome Modality in Patient
Population
To estimate the expected frequency of high chromo-
some modality in a prospective patient population, we
reviewed the Mitelman Database of Chromosome Aber-
rations in Cancer (see METHODS). The most prevalent
cases of high chromosome modality were found in
Hodgkin’s Lymphoma, Myeloma, and B-cell Acute Lym-
phocytic Leukemia. Conversely, AML and T-cell Acute
Lymphoblastic Leukemia subtypes had a lower preva-
lence of high chromosome modality (Table 3a).
For the GSK1070916 inhibitor, one prospective target
patient population is Non-Hodgkin’s B-cell Lymphoma.
To ascertain the relative frequency of high chromosome
modality in this patient population, frequency data for
Figure 2 Response vs. Chromosome Number. Response profile of GSK1070916 for various hematological cell line tumor types (n = 45). Those
cell lines that were responsive to treatment are on the left and those that were resistant are on the right. Higher chromosome numbers is more
prevalent for the less sensitive phenotypes.
Table 1 Response to GSK107916 among populations of
cells with high and low modal chromosome number in a
2 × 2 contingency table
Sensitive Resistant Total
Diploid (~2n) 16 13 33
High Modality (>3n) 21 4 12
Total 18 27 45
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reviewed. The distribution of high chromosome modal-
ity was varied with Diffuse Large B-Cell, Follicular, and
Mantle lymphoma subtypes having higher frequencies
compared to Burkitt and MALT NHL subtypes
(Table 3b).
Discussion
Karyotyping is a standard clinical practice for hematolo-
gical malignancies, and the cytogenetics of the disease
not only helps with diagnosis, but often provides prog-
nostic values [21-23]. With karyotype data from these
cell lines, we discovered that high chromosome number
in cell lines were associated with resistance to
GSK1070916. As with other Aurora B inhibitors, treat-
ment with GSK1070916 generally elicited a polyploidy
phenotype in cell lines. This suggests cancer cells with a
polyploid phenotype might have developed mechanisms
to bypass checkpoints for polyploidy and thus are resis-
tant to Aurora inhibition. Our comprehensive review of
publicly available karyotype data revealed subtypes of
hematological malignancies with high frequencies of
polyploidy. Conveniently, it is standard clinical practice
to perform karyotyping on hematological cancer cells
and chromosome number can serve as an attractive
resistance marker for patient response enrichment for
GSK1070916 in malignancies such as NHL.
An u m b e ro fA u r o r ak i n a s ei n h i b i t o r sa r ea l r e a d yi n
clinical or preclinical development including GSK1070916,
VX-680, AZD1152, PHA-739358, AT9283 and CYC116
[24-28]. Aurora kinase Inhibitors have shown potential
efficacy for a variety of hematological tumor subtypes
including AML, ALL and CML [29-33]. As with other tar-
geted therapies, predictive biomarkers for GSK1070916
that could stratify patient populations can accelerate clini-
cal development and cell line models have proven to be
Figure 3 The response profile of GSK1070916 for cell lines with a primary diploid chromosome number (<50).T h ep e r c e n t a g eo f
polyploidy within subpopulations of these cells is provided on the y axis. Resistant cell lines appeared to have elevated polyploidy among cell
subpopulations.
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hematological cell lines in our panel exhibited high sensi-
tivity using proliferation as a measure of response. This
sensitive response profile is likely due to the continuous
proliferating nature of the established cell lines in tissue
culture. Since cancer cell death is a more desired response
in clinic, measures of cell death were used as the criteria
to categorize response to GSK107016.
Using these criteria, our cell line panel exhibited sensi-
tivity with GSK1070916 in a broad range of leukemias
(AML, B-ALL, and CML) and two subtypes of NHL
(Burkitt’s, Large B-Cell Lymphoma). These findings are
generally consistent with response profiles observed
with other Aurora inhibitors [29,31,33] and suggests
these disease subtypes can serve as important predictors
of response.
Figure 4 Cell cycle distribution from fluorescent-activated cell sorting (FACs) analysis of T-ALL cell lines after treatment with
GSK1070916 at 24, 46, and 72 hours. (a) MOLT-16 was sensitive to GSK1070916 and showed increasing amounts of sub-2N DNA (blue)
indicating cell death.(b) In contrast, CTV-1 had higher amounts of 4N DNA or greater (light blue, green) which increased with prolonged
exposure to GSK1070916, generating a large multinucleated resistant phenotype.
Table 2 Association of NOTCH1 mutation status to high
modal chromosome number in T-ALL cell lines
WT Mutant NOTCH1 Total
Diploid (~2n) 72 9
High Modality (>3n) 21 214
Total 10 14 23
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were used to discover genetic markers with predictive
value. Cell lines with the polyploid phenotype were asso-
ciated with resistance to GSK1070916. This observation
was particularly striking in the response profile for T-
ALL cells in which a majority of cells (5/6) had both high
chromosome number and resistance to GSK1070916
with the sensitive cell line (MOLT-16) also having the
low chromosome phenotype. Not surprisingly, three
CML lines with hyperdiploidy (>2n) and hypertriploidy
(>3n) still maintained a sensitive response profile. The
sensitivity observed in CML cell lines, even with the poly-
ploid phenotype, was not unexpected since GSK1070916
inhibits ABL, and aurora kinase inhibitors that also inhi-
bit ABL can be considered a potential therapeutic alter-
native for patients resistant to Imatinib [35].
Cell lines and tumors can often exhibit heterogeneous
genetic backgrounds from diverse subpopulations. Upon
examination of the cell lines with low primary chromo-
some number, we found a higher proportion of polyploidy
among cell subpopulations in the resistant group. For
instance, in our panel of B-cell lymphoma cell lines, 6 of
the 7 cell lines were resistant to GSK1070916 and con-
tained low chromosome number in the primary popula-
tion of cells. However, when in reviewing the ploidy
content in the cell subpopulations in this tumor type, we
observe high ploidy content in numerous B-cell lymphoma
lines (e.g. REC-1, 25% polyploidy). This further under-
scores the significance of the general observation between
polyploidy and resistance. For these data, we hypothesize
there is a selective growth advantage for the subpopulation
of cells with the polyploid phenotype during Aurora inhi-
bition. This may represent a resistance mechanism that
potentially can develop upon prolonged drug treatment
with Aurora inhibitors. These findings warrant further
investigation about the relationship of chromosome num-
ber in primary and secondary populations of the tumor
during and after treatment to monitor potential evolving
resistance.
Inhibition of Aurora B does not inhibit cell cycle pro-
gression but rather enters and exits mitosis with normal
kinetics, with cells re-replicating their genome [36].
Treatment of cancer cells with GSK1070916 typically
yields a polyploid phenotype resulting from chromosome
replication without nuclear or cell division. Our FACS
analysis of GSK1070916 treatment shows that for sensi-
tive cells, polyploid cell populations would develop dur-
ing earlier time points and would be killed upon longer
drug incubation. For resistant cell lines, however, poly-
ploid cell populations were tolerated over time and sig-
nificantly less cell death was observed. To maintain
genome integrity, cells generally have developed mechan-
isms/checkpoints to prevent polyploidy [37]. It can be
hypothesized that for cells that are primarily polyploid,
they have developed mechanisms to bypass these check-
points to tolerate polyploidy and therefore can evade cell
death by AURKB/C inhibition. One of these mechanisms
could be p53 dependent tetraploidy checkpoint [38-40].
Interestingly, excluding cell lines with high chromosome
content (chromosome number >50 or polyploidy in >5%
of cell population), 4/5 sensitive lines were reported wild-
type for p53 while 3/4 resistant lines were p53 mutant
(Additional File 1, Table S5). These data further suggests
that inactivation of polyploidy checkpoints might contri-
bute to resistance during AURKB inhibition.
The expression profile for Aurora B and C in our panel
did not show any relationship with response to
GSK1070916 (Additional File 1, Table S4). However, since
the expression data in our panel does not reflect the rela-
tive expression of the Aurora genes at the time of mitosis,
the relationship of Aurora expression and response to
GSK1070916 is still unclear. In a subsequent analysis of
the background genetics, we found NOTCH1 mutation
status to be associated with high chromosome number in
T-ALL cells. In concordance with these findings, 3 of 4
resistant T-ALL cell lines with polyploidy also had muta-
tions in NOTCH1. While there was one AML cell line
(ML-2) with a NOTCH1 mutation which appeared to be
tetraploidy and was resistant to GSK1070916, a majority
of cell lines that were not T-ALL cell lines were wild-type
for NOTCH1. Since the association of NOTCH1 mutation
status with response to GSK1070916 was beyond the
scope of this study, no further data was collected to fully
confirm this relationship. While NOTCH activation has
been reported to be associated with tetraploidy and chro-
mosomal instability in meningiomas [41], the specific
mechanism by which these mutations may play in the for-
mation of the observed polyploid phenotype in T-ALL
cells has yet to be determined. Interestingly, NOTCH sig-
naling has also been considered to play a role in cancer
stem cell regulation [42] but it is unclear what role the
polyploid phenotype may play for these cell types.
Estimates of patient prevalence for a biomarker are cri-
tical for determining the appropriate patient selection
strategy. These estimates of prevalence can provide gui-
dance on the number of patients needed to screen for the
Table 3 Estimated frequency of high modality in major
hematological patient populations
Tumor Type >2n >3n Total Cases
AML 4.6% 1.5% 14,611
B-ALL 25.0% 2.0% 3,769
NHL - B-Cell 14.8% 8.2% 3,542
NHL - T-Cell 7.2% 5.1% 1,497
Hodgkins 48.8% 30.3% 244
T-ALL 5.9% 3.5% 1,130
Myeloma 39.8% 8.3% 1,561
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likely to provide a positive or negative response. The pre-
valence of the high modal chromosome number in
patients can be estimated using cytogenetic data publicly
available from the Mitelman database. We found the fre-
quency of high chromosome number is generally higher
among lymphoma compared to leukemia malignancies.
While the Hodgkin’s lymphoma subtype has an elevated
frequency of high chromosome modality in its patient
population, the NHL subtypes represent a population of
patients with a significant unmet medical need. Further
review of NHL subtypes showed that Follicular and Dif-
fuse Large B-Cell are the most promising as candidate
NHL subtypes for using high chromosome number as a
marker of negative response to Aurora inhibition. A
review of NOTCH mutations in the COSMIC data-
base [19] for T-ALL tumors show a mutation frequency
of 40% suggesting that T-ALL may also be a potentially
attractive subtype for patient stratification.
Conclusions
Identification of cytogenetic abnormalities using karyo-
typing for prognosis and treatment of hematological
malignancies has been a standard diagnostic tool for
many years [43-46]. Detection of polyploidy in cells,
with its ease of measurement, low costs, and biological
relevance as a negative predictor of response to Aurora
inhibition, can be a powerful tool to enrich patients that
can potentially respond to GSK1070916.
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